/
Invivyd, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of monoclonal antibody ( mAb ) therapies for the prevention and treatment of serious viral infectious diseases. We are devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, the virus that causes COVID-19.
The business is unprofitable at the operating level (-103.99% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 110.5% YoY with margins expanding 592.8pp.
Negative free cash flow of -$58M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$56M
▲ +110.5% YoY
Net Income (TTM)
-$78M
▲ +69.1% YoY
Op. Margin
-146.38%
▲ +592.8pp YoY
ROIC
-7.20%
▲ +8.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$79M
▲ +65.8% YoY
Op. Cash Flow (TTM)
-$79M
▲ +65.9% YoY
Net Debt
-$184M
Net Cash Position
Cash & Equiv.
$184M
Continue Research